The ESMO clinical practice guidelines for PCa recommend early PSA testing in BRCA1/2 carriers >40 years, and germline testing for BRCA2 and other DDR genes associated with cancer predisposition syndromes in men with a family history of cancer, and in all patients with metastatic prostate cancer. Here, BRCA2 is linked to posterior cortical atrophy.